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"The goal of breast cancer prevention research is to develop readily acceptable, 
minimally toxic, and affordable strategies that will reduce breast cancer incidence, 
morbidity, and mortality without inducing increased morbidity and mortality from 
other conditions."* 
* From the National Cancer Institute's Breast Cancer Progress Review Group 
Available: http://wwwosp.nci.nih.gov/planning/prg/bprgprevention.htm 
iii 
Report 
Effects of a novel anticancer agent on ras- and src- transformed 10TYl 
cells 
J ena Giltnane 
Dr. Hwa-Chang R. Wang, University of Tennessee Comparative Medicine Department 
I. Summary 
Breast cancer is second most deadly form of cancer among American women, and 
oncologists regularly screen potential anti-tumor agents for unique tumor-killing 
activity and selectivity for cancer cells. In this study, oncogene-transformed murine 
cells were used as target cells to investigate the cytotoxicity of a novel naturally 
occurring agent, FR901228 (FR), that has been shown to possess a potent antitumor 
activity against human and murine tumor cells. Investigation of the cytotoxicity of 
FR suggested that FR may be selective in targeting cancer cells, although some 
growth inhibition has been observed in normal cells. Further tests will be performed 
to investigate the biological and molecular activities of FR901228. 
II. Introduction 
Breast cancer 
Breast cancer and other cancers arise when certain mutations accumulate, and 
clonal selection begins to favor cells displaying aggressive growth rates (Fearon, 1043). 
Gene mutations identified in some human breast cancers include aberrations in identified 
genes BRCAI and BRCA2, although these mutations are not reliable predictors of 
developing breast cancer (Brody, no pg.). BRCAI and BRCA2 are both thought be 
involved in a protein interaction pathway which ultimately regulates the repair of some 
DNA damage (Fearon, 1047). In fact, there are many DNA mutations, which turn on or 
turn off important regulatory checkpoints in a cell's growth cycle, including errors 
introduced in oncogenes and tumor suppressor genes. 
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Oncogenes: ras and src proto-oncogenes and cancer 
An understanding of the biological and genetic basis of cancer and tumor 
proliferation began to develop from the discovery of viral oncogenes in early studies on 
RNA tumor retroviruses. Just as cancer is related at the cellular level to disorders in the 
control of cell proliferation, differentiation, and apoptosis (programmed cell death), it is 
associated with oncogenes and tumor suppressor genes at the genetic level. Potential 
DNA targets for oncogenic mutations are proto-oncogenes, which become "oncogenes" 
when activated by DNA changes in gene expression. 
Proto-oncongenes represent dominant mutations which result in an acceleration of 
cell growth promotion factors, while mutations in tumor suppressor genes are recessive, 
and "two hits" result in the loss of some inhibitory function of cell growth. The protein 
products of these genes are involved in many cell functions, including biochemical 
pathways for gene expression, the architecture and changes in the cell cytoskeleton, and 
cell metabolism. In both types of genetic damage, the result can be cells rapidly dividing 
with the loss of normal check-point systems-a tumor (pusztai, 47). 
In 1995, there were over one hundred oncogenes identified in human cancers, 
which are classified according to the how their normal proto-oncogene homologue 
functions in cell growth signal transduction pathways. There are currently four major 
classifications: abnormal signaling by a structurally abnormal growth factor, abnormal 
phosphorylation of proteins by altered receptors and signal transducer kinases, abnormal 
signaling by G proteins, and aberrant regulation of gene transcription by altered 
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transcription factors (pusztai,49). The cell line used in the experiment described here was 
transformed to represent cancerous mutations in both the ras and src oncogene families. 
Point mutations at identified codons in ras genes represent a classic example for 
mutational activation of a proto-oncogene. Genes in the ras family code for a major 
family of guanosine 5' triphosphate (GTP)-binding proteins, which are found at the inner 
surface ofthe plasma membrane and function to bind and hydrolyse GTP to GDP. They 
are cell messengers which intercept growth factor signals from receptors, and present 
them to internal secondary cell messengers (pusztai,55). 
The indication that a family of ras oncogenes was found to frequently contain 
mutations in human tumors caused one scientific group to screen novel products from 
bacterial fermentation broths for activity against ras-transformants (Veda 1994). They 
found that FR901228, the compund that is tested in this experiment, would selectively 
reverse the phenotype of a ras transformant, and identified this compound as a part of a 
new class of anticancer drug targeting the components of ras-mediated signaling 
transduction pathways (Veda, J. of Antibiot., I., 301). 
Some membrane-associated signal transducers are proteins with tyrosine kinase 
activity, which are recruited to the membrane and catalytically activated via growth 
factor receptors. The src family of proto-oncogenes belongs in this classification, because 
activated c-src is thought to bind intracellular targets such as P13K and GAP. Although 
not fully understood, the activation of src genes probably starts a complex tryosine 
phosphorylation cascade of many other proto-oncogene transcriptional factors, 
cytoskeleton proteins, and intermediate and effector signal transduction molecules 
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(Pusztai, 53-54). src-transformed cells were also tested in this experiment for comparison 
to normal and ras-transformed cells. 
Anti-Cancer Drug Discovery 
The drive in molecular oncology research is to develop new, more effective, and 
less toxic anticancer agents that will target specific gene changes and cutoff rapid 
division of tumor cells. Rapid new technologies are speeding up research, and researchers 
are quickly making insightful discoveries in cancer biology, moving toward 
understanding fully what the subtle changes in a cell's cycle may predict cancerous 
growth. If scientists can harness this new information to develop drugs with specific gene 
targets, we may be well on the road to effective treatment. 
The current drug discovery program at NCI begins with a screening of potential 
anticancer agents against 60 tumor cell lines, divided by tissue type (breast, pancreatic, 
colon, lung, etc.). From there, drugs which show promise move on to screening protocols 
in mice, including xenograft:s, in which human tumor cells are injected, grow, and are 
treated within immune-deficient mouse clones. Unique anticancer agents may move on to 
testing in larger animals, cytotoxicity tests, and human clinical trials. Only 1 drug in 
10,000 screened makes it to human trials, and only 20% of those tested in humans attain 
FDA approval (Available http://rex. nci. nih.govlmassmedialpressreleasesl 
discovery.html). 
Several problems exist with using murine models for oncogenic investigations. 
First, several mouse cancer models do not develop the same tumors seen in humans, and 
sometimes develop tumors unknown in human cases. Secondly, mice with engineered 
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cancer susceptibility do not develop cancers corresponding to human homologues at the 
expected rate (Fearon, 1049). Often, murine tumors will not show significant response to 
drug treatments known to work in humans. In fact, when researchers at NCI tested 12 
current anticancer agents, they find that 30 out of 48 tumor cell lines showed no response 
to drugs used in homologous tumors in humans (Gura,1041). Evidence of these 
shortcomings leave scientists looking for a better model. 
In August 1998, the National Cancer Institute identified the following goals for future 
modelling in breast cancer research: 
• Animal models with multiple genetic and epigenetic alterations that will more closely 
approximate human precancerous changes. 
• Viable precancerous tissue from which to establish cell lines and complete biomarker 
characterization of established cell lines. 
• Funding for long-term prospective human studies. 
• A central distribution source for cell lines and specialized animal models with on-line 
information available on both cell lines and animal models. 
(Available http://wwwosp.nci.nih.gov/planning/prg/bprgprevention.htm) 
FR901228: Discovery, structure and function in previous studies 
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FR901228 Depsipeptide {(E)-(IS,4S, 1 OS,21R)-7-[ (Z)-ethyl-idene-4,21-diisopropyl-2-oxa-12,13-dithia-
5,8,20,23-tetraazabicyclo-[8, 7 ,6]-tricos-l6-ene-3,6,9,22-pentanone} (Chassaing, 170) 
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First identified by Fujisawa Company in 1994, FR901228 (FR) is a bicyclic 
depsipeptide now in preclinical and early clinical development as an anticancer 
therapeutic agent (Chan, 195). The agent was isolated as prisms in a broth culture of 
Chromobacterium violaceum (No. 968) and when tested, the agent reverted the 
transformed morphology ofras-transformed cells to normal (Veda, J. of Antiobiot., I., 
301). 
Reviewing current research publications and selecting promising new agents for 
anti-cancer activity is part of the drug discovery program at the National Cancer Institute. 
In fact, NCl's Developmental Therapeutics Program has been responsible for the 
discovery andlor development of about one-half of chemotherapeutic drugs currently 
used for cancer treatment by oncologists (Press Release 1998). In 1998, NCI laboratories 
began to test FR in clinical trials as a potential therapeutic agent. More specifically, 
breast cancer is the second leading cause of cancer among women in the United States, 
and much time and funding has been devoted to the search for anticancer agents needed 
for selective therapy. 
In cytotoxicity tests in vitro, FR showed potent activity against human lung 
adenocarcinoma, lung squamous cell carcinoma, stomach adenocarcinoma, mammary 
carcinoma, and colon adenocarcinoma, and weak to no cytotoxic activity against human 
endothelial cells and human and mouse fibroblast cells (Veda, J. of Antibiot., I., 307). In 
in vivo murine tests, it prolonged the life of mice with leukemia and melanoma tumors, 
and inhibited the growth of both murine and human solid tumors implanted mice. (Ueda, 
1. of Antibiot., m., 315). Further studies in Japanese laboratories showed correlation 
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between treatment with FR and growth inhibition of ras-transformants, specifically 
GO/G1 cell cycle phase arrest (Veda, Biosci. Biotechnol.Biochem., 1579). 
Recently, an article in Breast Cancer Research and Treatment described the 
effects ofFR901228 on human breast cancer cells. This study revealed that FR induced 
"apoptotic-like" cell death in two human breast cancer cell lines, MCF7 and MDA-
MB231 (Rajgolikar, 29). The article included a protocol to test the cytotoxicity effect of 
FR on cancerous cell lines, which was used as a model for the study described here. 
If an agent such as FR901228 is found to have cancer cell-selective therapeutic 
activity in the earliest stages of drug development, it will be screened by anti-cancer 
laboratories for intensive analysis of cytotoxic effects and molecular mechanism of 
function. Dr. HCR Wang, a University of Tennessee professor in the Comparative 
Medicine Department is currently investigating such characteristics ofFR901228 in his 
laboratory. 
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III. Materials and methods 
Cell Cultures and determination of cell survival for cytotoxicity of anticancer agents 
Cells were grown in 12-well culture plates and treated at specific concentrations of two 
anticancer agents, FR901228 and staurosporin (STSP) over a period of 48 hours. After 
treatment, cells were rinsed with phosphate buffered saline (PBS), trypsinized for 2 
minutes, and neutralized with 5% Fetal Calf Serum (FCS)-containing Dulbecco's 
modified Eagle's medium (DMEM). Cells were harvested and resuspended in 0.2% 
Trypan blue/FCS-free DMEM for staining. Cell viability was determined in a 
hemocytometer, according to methods described elsewhere (Ausubel, Chapter 11). Dead 
cells exhibited stain uptake, while live cells were identified by stain exclusion, counted, 
and recorded. 
Statistical Analysis 
Each cell sample was counted in triplicate, and the original data sheets are included in 
this report (See Appendix). The average number of surviving cells was determined and 
compared to average number untreated cells at time zero (100%) to calculate relative 
survivability for each cell line and dosage amount, according to the following formula: 
(E1+E2+E3)!3 X (100%)= Relative Cell Survivability 
(CD1+CD2+CD3)/3 
(Where E= experimental cell data and CO= control cell data at time zero) 
These calculations were used to generate the following comparative charts on SigmaPlot 
4.0 for Windows; error bars represent standard deviation. 
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IV. Results 
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v. Discussion 
The preceding graphs show treatment of 10T1I2, ras-l0T1I2, andsrc-l0T1I2 cell 
lines with low, intermediate and high dosage concentrations ofFR901228 (FR) and 
staurosporin (STSP), an antitumor agent currently under investigation in other 
laboratories (Gurley 1998). Treatment with FR resulted in cell-line dependent effects, 
while STSP exhibited non-selective, dosage dependent growth inhibition effects. 
Normal lOT 112 cells showed dosage-dependent cell growth inhibition when 
treated with both FR and STSP. Low FR concentrations exhibited a slight inhibitive 
effect, increasing with dosage. The results of treatment with 5.0 nM suggests that 
cytotoxic effects may be seen in cells treated with 25.0 nM ofFR901228. 
Similarly, src-transformed 10T1I2 cells show dosage dependent growth inhibition 
in treatment with both agents. It is thought that src mutations have a widespread effect on 
cell functions, and so many other transcriptional and growth regulators and other proteins 
are affected. While FR may have some inhibitory effect on src-transformed cell lines, it 
would be extremely difficult to "rescue" src-transformed cell lines. 
ras-transformed lOT1I2 cells displayed interesting results when treated with FR. 
At 24 hours, all samples exhibited slight cell growth inhibition, increasing with dosage 
concentration. However, after 48 hours, there is a dramatic drop in cell survival from the 
untreated curve to the first dosage concentration at 0.2 nM. Morphology reversion to 
normal and apoptotic-like cell death is observed in all three dosages (for example of 
apoptotic like cell death, see (Wijsman 1993)). STSP treatment results are similar to 
effects observed in normal 10T1I2 cells. 
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Further analysis of the effects ofFR901228 on these cell lines is essential before 
many conclusions can be reached. According to the charts generated in this experiment, 
FR induced selective cell death in ras-transformed 10T1I2 cell line when compared to the 
normallOT1I2 cell1ine. This effect is not apparent in the src-transfonned lOT1I2 cell1ine. 
In order to confirm these findings, tests will be conducted by gel electrophoresis of DNA 
from treated cells, and it is expected that apoptotic death will result in fragmented DNA, 
readily distinguishable from cell death by necrosis. If apoptosis was indeed induced in 
these cell lines, it will be apparent after this analysis. 
An investigator at NCI, Dr. April Robbins, is working in collaboration with other 
scientists to discover the mechanism of action associated with the cell-growth inhibition 
and apoptotic induction caused by treatment with FR. In preliminary studies, her group 
has found that FR blocks cell growth in early prometaphase (Robbins, no pg.). 
IfFR901228 continues to exhibit promising experimental results such as the anti-
tumor effects displayed in this experiment in ras-transformed cells, perhaps we will be 
one step closer to understanding and unraveling the mysteries surrounding cancer 
treatment. 
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VIII. Appendix 
The following pages are copies of data entry sheets from February to April, 
1999, for cell line treatment with FR901228 and represent the data from which results 
(see page 9) were calculated. 
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